Description

Doximity Builds A Physician AI Powerhouse — Ask, Scribe & Decision Support Converge!

Doximity’s first quarter fiscal 2027 results showed continued revenue growth and increased investment in clinical artificial intelligence. Revenue rose 7% year-over-year to $157 million, exceeding the high end of guidance by 3%. Adjusted EBITDA reached $75 million, representing a 48% margin and an 8% outperformance versus guidance. Fiscal 2027 is being positioned as an AI investment year while maintaining strong software margins. The independent NOHARM study, led by Stanford and Harvard researchers, evaluated 24 clinical AI models using real-world cases. Doximity’s Ask ranked as the leading U.S. model, with the lowest clinical error rate at 4.8% and highest safety ratings, compared with Anthropic’s Fable 5 at 13.6%. Doximity attributes this performance to its expert-verified proprietary drug reference system and more than 12,000 physician PeerCheck editors. Enterprise adoption has reached 165 health system AI clients, including several top-ranked hospitals, as adoption increasingly emphasizes privacy, safety, and accuracy.